AKT1 and thyroid cancer: It has been reported that miR-17-5p could inhibited PTEN expression, therefore leading to suppression of the malignancy of thyroid cancer and inactivation of AKT/mTOR pathway, providing a novel avenue for treatment of thyroid cancer [20].